PLEASE NOTE : This is a development system.
For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.
For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.
You are here : Home > PAD Profile : Vardenafil - Benign prostatic hyperplasia
PAD Profile : Vardenafil - Benign prostatic hyperplasia
Keywords :
BPH, LUTS, urinary tract symptoms, urinary frequency, urinary incontinence
Brand Names Include :
Levitra
Traffic Light Status
Status 1 of 1.
Guidelines
No guidelines returned.
Other Drugs
- Tadalafil
- Tamsulosin and dutasteride hydrochloride
- Alfuzosin hydrochloride
- Tamsulosin hydrochloride
- Doxazosin mesilate
- Terazosin hydrochloride
- Indoramin
- Prazosin hydrochloride
- Sildenafil (Erectile Dysfunction)
- Avanafil
- Solifenacin/tamsulosin
Other Indications
Additional Documents
Type
Document
Review Date
Policy Statement
Phosphodiesterase-5 inhibitors for urinary tract symptoms in men - Policy statement PCN 294-2017 - D
01 June 2025
Committee Recommendations
Date
Committee Name
Narrative
03 June 2020
Surrey & North West Sussex Area Prescribing Committee (formerly Prescribing Clinical Network)
At the Surrey and North-West Sussex Area Prescribing Committee (APC) held in June 2020, it was decided that all BLACK status drugs would have their review dates extended for 5 years without the need for a review.
If a clinician or provider wishes to change the traffic light status of any BLACK drug then they will need to submit a paper for change as per usual APC process.
06 December 2017
Surrey & North West Sussex Area Prescribing Committee (formerly Prescribing Clinical Network)
The PCN does not recommend the use of phosphodiesterase-5 inhibitors for the treatment of lower urinary tract symptoms in men (except as part of a randomised controlled trial) and has assigned a traffic light status to each treatment option as follows.
- Sildenafil - BLACK
- Tadalafil – BLACK
- Avenafil - BLACK
- Vardenafil – BLACK
Patients whose treatment with the above, that were initiated by the NHS before this recommendation was made, must be reviewed by their NHS consultant but should be able to continue treatment until the patient and their NHS consultant consider it appropriate to stop.
Associated BNF Codes
07. Obstetrics, Gynaecology and Urinary-Tract Disorders
07.04.01. Drugs for urinary retention